Reaching the target dose with one single I-mIBG administration in high-risk neuroblastoma: The determinant impact of the primary tumour.

Background: I-metaiodobenzylguanidine ( I-mIBG) effectiveness in children with metastasised neuroblastoma (NB) is linked to the effective dose absorbed by the target; a target of 4 Gy whole-body dose threshold has been proposed. Achieving this dose often requires administering I-mIBG twice back-to-back, which may cause haematological toxicity. In this study, we tried identifying the factors predicting the achievement of 4 Gy whole-body dose with a single radiopharmaceutical administration.